Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 2 7Phase NA 2Phase 3 2Phase 4 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 263Leukemia 190Leukemia, Lymphocytic, Chronic, B-Cell 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Myelodysplastic Syndromes 83Lymphoma 79Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Hematologic Neoplasms 62Lymphoma, Non-Hodgkin 61Lymphoma, Follicular 54Leukemia, Myeloid, Chronic-Phase 53Burkitt Lymphoma 51Lymphoma, Large B-Cell, Diffuse 47Lymphoma, B-Cell, Marginal Zone 45Lymphoma, Mantle-Cell 44Multiple Myeloma 42Leukemia, Myelomonocytic, Chronic 41Hodgkin Disease 41Myeloproliferative Disorders 38Neoplasms 37Lymphoma, Large-Cell, Immunoblastic 37Recurrence 31Leukemia, Myeloid, Accelerated Phase 28Congenital Abnormalities 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Biphenotypic, Acute 26Lymphoma, T-Cell, Cutaneous 25Blast Crisis 24Waldenstrom Macroglobulinemia 23Leukemia, Myelomonocytic, Acute 23

Interventions

ponatinib 1amonafide 1Imatinib Mesylate 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphatic Diseases × Other hematologic neoplasm × Clear all
NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Antisoma Research

Phase 3 Unknown
420 enrolled
Other hematologic neoplasm

Leukemia, Lymphatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡